The BioNTech SE ADR BNTX rallied 1.59% to $117.64 Thursday, on what proved to be an all-around favorable trading session for ...

Fintel reports that on September 24, 2024, Morgan Stanley upgraded their outlook for BioNTech SE - Depositary Receipt () ...

The BioNTech SE ADR BNTX rose 4.79% to $118.47 Tuesday, on what proved to be an all-around great trading session for the ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 ...

GSK's decision not to advance the vaccine into Phase III trials ends its ambition to bring the first HSV vaccine to market.

Health Canada recently asked provinces and territories to get rid of their older COVID-19 vaccines to ensure the most current ...

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...

Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

OncoC4 is taking AcroImmune—and its in-house clinical manufacturing capabilities—under its wing in an all-stock merger. | ...

2-adapted vaccine and the clinical and real-world evidence supporting the safety and efficacy of prior formulas of the COVID-19 vaccines by Pfizer and BioNTech. The non-clinical data showed that ...